MARCH-I expression in cord blood CD34+KDR+ cells.

Clin Biochem

Department Experimental Oncology, Mediterranean Institute of Oncology, Viagrande, Catania, Italy.

Published: June 2011

Hematopoietic stem cells transplantation has been successfully used in the treatment of patients with hematological malignances. A better knowledge of the mechanisms beyond their ability to completely repopulate the entire hematopoietic system would help in the treatment of hematological diseases. For this reason we focused our studies on a cell population that has been demonstrated to have some peculiar characteristics among the stem cells: CD34+KDR+ cells. These cells, an extremely rare population among the CD34 (0.1%-0.5%) cells, have been demonstrated from different groups to have the potential to give rise to the hematopoietic and endothelial lineage. By a subtraction library approach we found different sequences more expressed in CD34+KDR+ than their CD34+KDR- counterpart. In particular, we found an open reading frame correspondent to a newly characterized E3 ligase, MARCH-I. This gene is part of a recently described family involved in immune response modulation through the proteosomal mediated degradation. MARCH-I expression in stem cells could be important for their intrinsic immune properties.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinbiochem.2011.02.011DOI Listing

Publication Analysis

Top Keywords

stem cells
12
march-i expression
8
cd34+kdr+ cells
8
cells
7
expression cord
4
cord blood
4
blood cd34+kdr+
4
cells hematopoietic
4
hematopoietic stem
4
cells transplantation
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!